Form 4: VolitionRx CEO's RSU Vesting & Tax Withholding

VolitionRx's CEO of Volition Veterinary, Salvatore Thomas Butera, reported a disposition of 6,393 common shares for tax withholding related to restricted stock unit vesting.

Summary

• Salvatore Thomas Butera, CEO of Volition Veterinary at VolitionRx Ltd (VNRX), reported a change in beneficial ownership.
• On August 1, 2025, 6,393 shares of common stock were disposed of to VolitionRx.
• This disposition was to satisfy tax withholding obligations upon the settlement of 23,377 restricted stock units (RSUs).
• The RSUs were awarded in lieu of cash compensation.
• No shares were sold by the reporting person or VolitionRx in this transaction.
• Following the transaction, Salvatore Thomas Butera beneficially owns 303,524 shares directly and 99,350 shares jointly with his spouse, totaling 402,874 shares.
• The shares were valued at $0.64 for the purpose of tax withholding.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction related to RSU vesting and tax withholding. It is a neutral event, leaning slightly positive as it confirms executive compensation and retention without an open market sale.

Positives

• The transaction represents the vesting of restricted stock units, indicating compensation for the CEO.
• No shares were sold by the reporting person or the company in the open market, indicating the disposition was solely for tax purposes.

Future Outlook

The filing does not contain forward-looking statements or guidance, as it is a report of a past insider transaction.

Industry Context

This Form 4 filing is a routine disclosure of an insider's equity transaction, specifically related to restricted stock unit vesting and tax withholding. It does not provide broader industry context or competitive analysis.

Comparison to Industry Standards

• This filing is a standard Form 4 for reporting insider transactions.
• The details of RSU vesting and tax withholding are common practices for executive compensation across industries.
• No specific comparable companies or projects are mentioned or implied.

Related Party Transactions

• The disposition of shares to VolitionRx for tax withholding purposes upon RSU settlement can be considered a related party transaction between the company and its officer.

Stakeholder Impact

• Shareholders: Minimal direct impact as it's a routine tax withholding, not an open market sale that would dilute or significantly affect share price. It confirms executive compensation practices.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the disposition of shares for tax withholding upon RSU vesting. It does not indicate any fundamental change in the company's operations, financial health, or strategic direction that would warrant a change in investment recommendation. It's a neutral event that confirms standard executive compensation practices.

Keywords

VolitionRx, VNRX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Tax Withholding, Salvatore Thomas Butera, CEO Volition Veterinary, Beneficial Ownership